Event: Solebury Trout Class of 2018 Biotech IPOs Investor Day
Location: Davis Polk Offices,
A live and archived webcast of the presentation can be accessed by visiting the Investors page of the website at https://investors.surfaceoncology.com/news-events/events.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on NZV930 (CD73) and potentially one additional undisclosed program. For more information, please visit www.surfaceoncology.com.
Ten Bridge Communications
Source: Surface Oncology, Inc.